Radiation therapy in the management of the inguinal region in penile cancer: What's the evidence?

Urol Oncol. 2022 Jun;40(6):223-228. doi: 10.1016/j.urolonc.2020.05.004. Epub 2020 May 29.

Abstract

Due to its rarity and lack of prospective studies, clinical evidence for the management of the inguinal lymphatic nodal basin with radiation therapy in penile cancer (PeCa) has been limited. In this report, we review the current literature and further investigated the landscape of radiation sensitivity in nodal metastases of PeCa utilizing our well-established genome-based radiosensitivity index (RSI) platform. We hypothesized that optimal therapeutic gain could be achieved in PeCa stratified by the combination of clinicopathological parameters, genomic heterogeneity, and RSI-based radiation dose prescription (RxRSI). Similar to primary PeCa lesions, we found that the majority of PeCa nodal metastases are genomically radioresistant with significant heterogeneity. RxRSI should be considered to inform and optimize the radiation therapy dose prescription to the individual tumor biology.

Keywords: Biomarker stratification; Inguinal lymph nodes; Penile cancer; RSI; Radiotherapy.

Publication types

  • Review

MeSH terms

  • Genomics
  • Humans
  • Lymph Node Excision
  • Male
  • Penile Neoplasms* / pathology